ILA Stock Overview
Island Pharmaceuticals Limited, a drug research and repurposing company, focuses on the development of preventative or therapeutic drugs for viral infections.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Island Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.055 |
| 52 Week High | AU$0.14 |
| 52 Week Low | AU$0.055 |
| Beta | 0.32 |
| 1 Month Change | -8.33% |
| 3 Month Change | -33.73% |
| 1 Year Change | -29.49% |
| 3 Year Change | -84.72% |
| 5 Year Change | n/a |
| Change since IPO | -89.52% |
Recent News & Updates
Recent updates
Shareholder Returns
| ILA | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | -11.3% | -3.0% | -2.2% |
| 1Y | -29.5% | 37.1% | 4.5% |
Return vs Industry: ILA underperformed the Australian Pharmaceuticals industry which returned 37.1% over the past year.
Return vs Market: ILA underperformed the Australian Market which returned 4.5% over the past year.
Price Volatility
| ILA volatility | |
|---|---|
| ILA Average Weekly Movement | 10.2% |
| Pharmaceuticals Industry Average Movement | 11.1% |
| Market Average Movement | 9.0% |
| 10% most volatile stocks in AU Market | 17.6% |
| 10% least volatile stocks in AU Market | 3.4% |
Stable Share Price: ILA's share price has been volatile over the past 3 months.
Volatility Over Time: ILA's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | n/a | David Foster | www.islandpharmaceuticals.com |
Island Pharmaceuticals Limited, a drug research and repurposing company, focuses on the development of preventative or therapeutic drugs for viral infections. Its lead product candidate is ISLA-101, a drug for the prevention and treatment of dengue fever and other mosquito borne diseases. The company has a research collaboration agreement with Monash University to screen known molecules against host targets; research and development collaboration with Griffith University to screen for active anti-viral molecules in a rational repurposing strategy; and research collaboration agreement with Compounds Australia, a drug library containing various molecules that could be searched for drug re-purposing and pipeline development.
Island Pharmaceuticals Limited Fundamentals Summary
| ILA fundamental statistics | |
|---|---|
| Market cap | AU$6.26m |
| Earnings (TTM) | -AU$2.37m |
| Revenue (TTM) | AU$960.12k |
6.5x
P/S Ratio-2.6x
P/E RatioIs ILA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ILA income statement (TTM) | |
|---|---|
| Revenue | AU$960.12k |
| Cost of Revenue | AU$610.56k |
| Gross Profit | AU$349.56k |
| Other Expenses | AU$2.72m |
| Earnings | -AU$2.37m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.021 |
| Gross Margin | 36.41% |
| Net Profit Margin | -247.34% |
| Debt/Equity Ratio | 79.6% |
How did ILA perform over the long term?
See historical performance and comparison